Łukasz Zapała

发表

Feasibility of active surveillance in small testicular mass: a mini review

T. Borkowski, P. Radziszewski, A. Cudnoch-Jędrzejewska, 2021, Central European journal of urology.

Immune checkpoint receptor VISTA on immune cells is associated with expression of T-cell exhaustion marker TOX and worse prognosis in renal cell carcinoma with venous tumor thrombus

W. Biernat, P. Radziszewski, R. Pęksa, 2022, Journal of Cancer Research and Clinical Oncology.

Development and validation of a prognostic model incorporating tumor thrombus grading for nonmetastatic clear cell renal cell carcinoma with tumor thrombus: A multicohort study

N. Xu, R. Chen, C. Liang, 2023, MedComm.

Prediction of BCG responses in non-muscle-invasive bladder cancer in the era of novel immunotherapeutics

P. Radziszewski, Aleksander Ślusarczyk, Piotr Zapała, 2019, International Urology and Nephrology.

Prostate Cancer in Transplant Receivers—A Narrative Review on Oncological Outcomes

Piotr Zapała, Ł. Zapała, Karolina Hanusz, 2023, Biomedicines.

E-Cadherin, Integrin Alpha2 (Cd49b), and Transferrin Receptor-1 (Tfr1) Are Promising Immunohistochemical Markers of Selected Adverse Pathological Features in Patients Treated with Radical Prostatectomy

P. Radziszewski, B. Gornicka, Z. Lewandowski, 2021, Journal of clinical medicine.

Advances in the Treatment of Kidney and Upper Urinary Tract Cancers

P. Rajwa, Łukasz Zapała, 2024, Biomedicines.

The Cannabinoid Ligand Arachidonyl-2′-Chloroethylamide (ACEA) Ameliorates Depressive and Overactive Bladder Symptoms in a Corticosterone-Induced Female Wistar Rat Model

P. Radziszewski, A. Wróbel, A. Wdowiak, 2023, International journal of molecular sciences.

The Four-Feature Prognostic Models for Cancer-Specific and Overall Survival after Surgery for Localized Clear Cell Renal Cancer: Is There a Place for Inflammatory Markers?

P. Radziszewski, Aleksander Ślusarczyk, Piotr Zapała, 2022, Biomedicines.

The effect of O-1602, a GPR55 agonist, on the cyclophosphamide-induced rat hemorrhagic cystitis.

P. Radziszewski, A. Wróbel, Piotr Zapała, 2020, European journal of pharmacology.

Therapeutic metastatic prostate cancer vaccines: lessons learnt from urologic oncology

W. Lasek, Ł. Zapała, Łukasz Zapała, 2021, Central European journal of urology.

Patterns of care in patients with muscle-invasive bladder cancer – a retrospective cohort study

S. Poletajew, P. Radziszewski, S. Czarniecki, 2016, Contemporary oncology.

Neutrophil-to-lymphocyte ratio predicts nodal involvement in unfavourable, clinically nonmetastatic prostate cancer patients and overall survival in pN1 patients

B. Pradère, P. Radziszewski, Z. Lewandowski, 2023, Scientific Reports.

Interobserver variability of Clavien–Dindo scoring in urology

S. Poletajew, P. Radziszewski, P. Świniarski, 2014, International journal of urology : official journal of the Japanese Urological Association.

Can We Go beyond Pathology? The Prognostic Role of Risk Scoring Tools for Cancer-Specific Survival of Patients with Bladder Cancer Undergoing Radical Cystectomy

P. Lipiński, Grzegorz Niemczyk, Aleksander Ślusarczyk, 2024, Biomedicines.

Oncologic outcomes of patients treated with kidney-sparing surgery or radical nephroureterectomy for upper urinary tract urothelial cancer: a population-based study.

M. Moschini, P. Rajwa, E. Laukhtina, 2023, Urologic oncology.

The GPR39 Receptor Plays an Important Role in the Pathogenesis of Overactive Bladder and Corticosterone-Induced Depression

P. Dobrowolski, I. Sadok, A. Wdowiak, 2024, International Journal of Molecular Sciences.

Not as black as it is painted? The impact of the first wave of COVID-19 pandemic on surgical treatment of urological cancer patients in Poland – a cross-country experience

P. Jarzemski, B. Małkiewicz, W. Krajewski, 2021, Archives of medical science : AMS.